Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ANCN

Anchiano Therapeutics (ANCN) Stock Price, News & Analysis

Anchiano Therapeutics logo

About Anchiano Therapeutics Stock (NASDAQ:ANCN)

Advanced Chart

Key Stats

Today's Range
$1.34
$1.39
50-Day Range
$2.82
$59.00
52-Week Range
$0.51
$10.55
Volume
137,995 shs
Average Volume
3.15 million shs
Market Capitalization
$10.13 million
P/E Ratio
9.10
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Receive ANCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anchiano Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANCN Stock News Headlines

ITeos Therapeutics Inc Ordinary Shares
Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
ENDV Endonovo Therapeutics, Inc.
See More Headlines

ANCN Stock Analysis - Frequently Asked Questions

Anchiano Therapeutics Ltd. (NASDAQ:ANCN) released its quarterly earnings results on Monday, August, 5th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.12.

Anchiano Therapeutics (ANCN) raised $35 million in an initial public offering on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Anchiano Therapeutics investors own include BioCryst Pharmaceuticals (BCRX), Bionano Genomics (BNGO), Cheniere Energy (LNG), Ocugen (OCGN), Agenus (AGEN), Allena Pharmaceuticals (ALNA) and Aileron Therapeutics (ALRN).

Company Calendar

Last Earnings
8/05/2019
Today
5/24/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ANCN
CIK
N/A
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Trailing P/E Ratio
9.10
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-27,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.01 per share
Price / Book
0.68

Miscellaneous

Free Float
N/A
Market Cap
$10.13 million
Optionable
Not Optionable
Beta
0.93
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:ANCN) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners